ArticleClinical case reports2025
Thrombolytic Therapy for Massive Pulmonary Embolism in an Antiphospholipid Syndrome Patient With Severe Thrombocytopenia: A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thrombolytic Therapy in High-Risk Pulmonary Embolism with Thrombocytopenia: Case Report and Literature Review.Journal of clinical medicine · 2026Article
- Thrombolytic Therapy for Massive Pulmonary Embolism in an Antiphospholipid Syndrome Patient With Severe Thrombocytopenia: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombocytopenia (TCP) is a well-known contraindication for thrombolytic therapy due to the associated risk of bleeding. This report discusses a 34-year-old woman presented with massive pulmonary embolism (PE) and severe TCP. She was treated with systemic thrombolysis (ST), and fortunately, a good therapeutic response was achieved without significant bleeding. Further evaluations confirmed the diagnosis of antiphospholipid syndrome for the patient. This case highlights that ST can be a viable therapeutic option for managing massive PE in thrombocytopenic patients under specific circumstances, warranting further research into its safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.